Chad Pawlak, Sr. brings over 30 years of experience with a proven track record of driving revenue growth and fostering strategic partnerships across agribusiness and sustainability – particularly in soil and water conservation. He has a deep understanding of regenerative agriculture, biotechnology, crop cultivation and consumer packaged goods (CPG). Most recently he was CEO of Locus Agricultural Solutions, an agricultural biological company, where he led the strategic growth plan through cross-functional collaboration, resulting in over 350,000 acres of enrollment in a nature-based carbon credit project utilizing a biological product as the practice change. Chad has previous experience as the U.S.-Canada Crop & Plant Protection Business Director Lead – Botanicals for MGK (a part of Valent USA & Sumitomo Chemical). In this role, he was responsible for the overall design of the strategic business plan of the $30 million Botanical & Organic Crop Protection segments in the U.S. & Canada. He holds an MBA from the Jack Welch Management Institute and BS & AOS in Marketing and Advertising/Public Relations from Johnson & Wales University.
Judith S. Miller is a member of the Florida Bar, living in Chapel Hill, North Carolina. Judith was a seed-investor in the precursor company that became the current Genvor Incorporated. The Board asked her to step into an Interim CEO Role in 2023, later transitioning to Chief Business Officer with the January 2024 appointment of Chad Pawlak as CEO. Judith has served as a Business Strategist for both domestic and international entities, is a Real Estate Developer, and an award-winning Film & Theater Producer. Judy earned both her BAED and JD from the University of Florida where she also was an Instructor of Business Law.
Dr. Jaynes is a Co-Founder and Board Member for Genvor. He leads the research for Genvor and manages ongoing, critical communication with our outside research and development partners and associations. Dr. Jaynes is one of the world’s leading authorities on therapeutic peptide design and has vast experience in drug development for various applications, including agriculture, animal health, wound healing, and oncology. Dr. Jaynes’ research is funded by USDA, NSF, and NIH. He has more than 60 United States and foreign patents and has authored over 100 scientific journal articles. Over the past 15 years, Dr. Jaynes has served on the board of numerous life science companies and is currently the Chief Technology Officer for the National Cancer Coalition. Dr. Jaynes is a Professor of Biochemistry at Tuskegee University. Dr. Jaynes completed his doctoral training at Brigham Young University, Utah.
Dr. Yates co-founded Genvor and is a Board Member. His research is currently funded by the National Cancer Institute (NCI) and Department of Defense (DOD) Congressionally Medical Directed Research Programs. Dr. Yates is also scientist at Tuskegee University, focused on identifying molecular targets for therapeutic intervention in prostate, breast, and pancreatic cancers. Dr. Yates received his initial training at the University of Pittsburgh School of Medicine in department of Cellular and Molecular Pathology. He completed additional training in Tissue Engineering and Regenerative Medicine jointly from the McGowan Institute for Regenerative Medicine and Massachusetts Institute of Technology (MIT). Dr. Yates completed his post-doctoral training at Emory University School of Medicine in the Department of Molecular Urology.
Dr. Dean-Colomb is a medical oncologist and physician-scientist. She also has board certification from the American Board of Internal Medicine and is a practicing physician in Louisiana. Dr. Dean-Colomb conducts research across an array of molecular structures affecting all living organisms, as well as has an active research program focused on understanding the metabolism profile of women with triple-negative breast cancer. Dr. Dean-Colomb earned her Doctor of Medicine Degree and PhD in Toxicology from the University of Illinois in Urbana, IL and completed her Oncology fellowship at M.D. Anderson Cancer Center in Houston, Tx.